Paolo Pucci
Director/Board Member presso WEST PHARMACEUTICAL SERVICES, INC.
Patrimonio netto: 4 M $ in data 31/03/2024
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Philip Astley-Sparke | M | 52 | 9 anni | |
| Bill Lundberg | M | 60 | 5 anni | |
| Robert Coffin | M | 59 | 9 anni | |
| Kapil Dhingra | M | 64 | 12 anni | |
| Peter Silverman | M | 46 | 7 anni | |
| Sushil Patel | M | 53 | 3 anni | |
| Bernard Birkett | M | 55 | 6 anni | |
| Eric Green | M | 55 | 9 anni | |
| Gregory Perry | M | 63 | 8 anni | |
| Mark Iwicki | M | 57 | 9 anni | |
| Sushant Kumar | M | - |
Tarus Therapeutics, Inc.
 Tarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Portage Biotech, Inc., Tarus Therapeutics, Inc. is a private company developing small molecule inhibitors of adenosine receptors for cancer immunotherapy and select non-oncology indications. The company is based in New York, NY. The company has a comprehensive portfolio of adenosine receptor antagonists in development, including both first-in-class and programs. The company was founded by Sushant Kumar and Peter R. Molloy, with Sushant Kumar serving as CEO since incorporation. Tarus Therapeutics was acquired by Portage Biotech, Inc. on July 05, 2022 for $49.20 million. | - |
| Dieter Weinand | M | 63 | 6 anni | |
| Anand Mehra | M | 48 | 9 anni | |
| Christy Oliger | F | 54 | 3 anni | |
| Robert Glassman | M | 62 |
Tarus Therapeutics, Inc.
Tarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Portage Biotech, Inc., Tarus Therapeutics, Inc. is a private company developing small molecule inhibitors of adenosine receptors for cancer immunotherapy and select non-oncology indications. The company is based in New York, NY. The company has a comprehensive portfolio of adenosine receptor antagonists in development, including both first-in-class and programs. The company was founded by Sushant Kumar and Peter R. Molloy, with Sushant Kumar serving as CEO since incorporation. Tarus Therapeutics was acquired by Portage Biotech, Inc. on July 05, 2022 for $49.20 million. | 3 anni |
| Andrew Schwendenman | M | 48 | 4 anni | |
| Silji Abraham | M | 52 | 6 anni | |
| Kimberly MacKay | F | 58 | 4 anni | |
| Victor Sandor | M | 57 | 5 anni | |
| Len Kanavy | M | 62 | 6 anni | |
| Cindy Reiss-Clark | F | 50 | - | |
| Sherri L. Spear | F | - | - | |
| Andrew Muratore | M | - | 3 anni | |
| Deborah Baron | F | 55 | 3 anni | |
| Deborah Keller | F | 61 | 7 anni | |
| Molly Joseph | F | 50 | 3 anni | |
| David Epstein | M | 62 |
Tarus Therapeutics, Inc.
Tarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Portage Biotech, Inc., Tarus Therapeutics, Inc. is a private company developing small molecule inhibitors of adenosine receptors for cancer immunotherapy and select non-oncology indications. The company is based in New York, NY. The company has a comprehensive portfolio of adenosine receptor antagonists in development, including both first-in-class and programs. The company was founded by Sushant Kumar and Peter R. Molloy, with Sushant Kumar serving as CEO since incorporation. Tarus Therapeutics was acquired by Portage Biotech, Inc. on July 05, 2022 for $49.20 million. | 4 anni |
| Colin Love | M | 66 | 9 anni | |
| Douglas Michels | M | 66 | 13 anni | |
| William Feehery | M | 54 | 12 anni | |
| Robert Friel | M | 68 | 4 anni | |
| Thomas Hofmann | M | 72 | 17 anni | |
| Myla Lai-Goldman | M | 66 | 10 anni | |
| Joseph Slattery | M | 59 | 7 anni | |
| Mark Buthman | M | 63 | 13 anni | |
| Veleka Peeples-Dyer | F | 52 | 1 anni | |
| Hyam Levitsky | M | 66 | 6 anni | |
| Peter Molloy | M | 52 |
Tarus Therapeutics, Inc.
Tarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Portage Biotech, Inc., Tarus Therapeutics, Inc. is a private company developing small molecule inhibitors of adenosine receptors for cancer immunotherapy and select non-oncology indications. The company is based in New York, NY. The company has a comprehensive portfolio of adenosine receptor antagonists in development, including both first-in-class and programs. The company was founded by Sushant Kumar and Peter R. Molloy, with Sushant Kumar serving as CEO since incorporation. Tarus Therapeutics was acquired by Portage Biotech, Inc. on July 05, 2022 for $49.20 million. | - |
| Stephen Lockhart | M | 65 | 2 anni | |
| John de Kruif | M | 60 | 17 anni | |
| Christopher Sarchi | M | 56 | 1 anni | |
| Konstantinos Xynos | M | 58 | 2 anni | |
| Michele Polinsky | M | - | - | |
| Robert Segura | M | - | 3 anni | |
| Donald A. McMillan | M | 65 | 27 anni | |
| Ernesto Wasserman | M | - | 8 anni | |
| Shannon Campbell | F | - | 2 anni | |
| Chris Ryan | M | - | - | |
| Kathleen Farren | F | - | - | |
| Alexander Berthold Hendrik Bakker | M | 57 | 14 anni | |
| Paul Achleitner | M | 67 | 22 anni | |
| Andrew Joe | M | 58 | 4 anni | |
| Harry Shuman | M | - | - | |
| Maxine Gowen | M | 66 | 3 anni | |
| Mark S. Cohen | M | 56 |
Tarus Therapeutics, Inc.
Tarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Portage Biotech, Inc., Tarus Therapeutics, Inc. is a private company developing small molecule inhibitors of adenosine receptors for cancer immunotherapy and select non-oncology indications. The company is based in New York, NY. The company has a comprehensive portfolio of adenosine receptor antagonists in development, including both first-in-class and programs. The company was founded by Sushant Kumar and Peter R. Molloy, with Sushant Kumar serving as CEO since incorporation. Tarus Therapeutics was acquired by Portage Biotech, Inc. on July 05, 2022 for $49.20 million. | 3 anni |
| Emily Hill | F | 44 | 1 anni | |
| Arleen Goldenberg | F | - | - | |
| Chad Winters | M | 45 | 5 anni | |
| Quintin Lai | M | 57 | 8 anni | |
| Annette Favorite | F | 59 | 9 anni | |
| C. Nicholson | M | 68 |
Tarus Therapeutics, Inc.
Tarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Portage Biotech, Inc., Tarus Therapeutics, Inc. is a private company developing small molecule inhibitors of adenosine receptors for cancer immunotherapy and select non-oncology indications. The company is based in New York, NY. The company has a comprehensive portfolio of adenosine receptor antagonists in development, including both first-in-class and programs. The company was founded by Sushant Kumar and Peter R. Molloy, with Sushant Kumar serving as CEO since incorporation. Tarus Therapeutics was acquired by Portage Biotech, Inc. on July 05, 2022 for $49.20 million. | 4 anni |
| Liu Hui | M | 51 | 9 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 36 | 36.36% |
| Svizzera | 27 | 27.27% |
| Paesi Bassi | 18 | 18.18% |
| Germania | 10 | 10.10% |
| Canada | 8 | 8.08% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Paolo Pucci
- Contatti personali
